Micron Biomedical secured $16 million in a Series A3 funding round, bringing the total Series A investment to over $33 million. This funding, led by J2 Ventures and the Global Health Investment Corporation (GHIC), will expand the commercial manufacturing of Micron’s needle-free drug and vaccine delivery technology based on dissolvable microarrays. The company recently received grants from CEPI, BARDA, and the Bill & Melinda Gates Foundation for developing needle-free vaccines for various diseases, including Disease X, influenza, and measles/rubella.
This investment significantly advances Micron Biomedical’s capacity to address pressing global health challenges by improving access to essential medications and vaccines. The needle-free technology offers a solution for populations with limited access to healthcare professionals, simplifies administration, and improves patient comfort. This is especially relevant for global health initiatives, military applications, and emergency response scenarios. Thermostable properties also remove the need for complex cold chain logistics, significantly broadening the reach of life-saving medications, especially in resource-limited settings.
This funding round builds upon substantial financial backing from prominent institutions, highlighting the growing recognition of Micron’s technology’s potential. The expansion of commercial manufacturing capabilities will enable the company to scale production and move closer to widespread distribution of its products. Dr. Matt Goldman, General Partner at J2 Ventures and former Chief Medical Officer of the Defense Innovation Unit, joins Micron’s board, bringing valuable expertise in both military and civilian medical applications.
This latest funding round represents a crucial step toward making needle-free drug and vaccine administration a reality. It paves the way for increased production, broader distribution, and ultimately, greater accessibility to critical medications and vaccines worldwide. The addition of Dr. Goldman to the board signals a strategic focus on expanding into both civilian and military markets, further solidifying Micron’s potential for long-term growth and impact.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
